DK3151851T3 - Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme - Google Patents

Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme Download PDF

Info

Publication number
DK3151851T3
DK3151851T3 DK15728491.0T DK15728491T DK3151851T3 DK 3151851 T3 DK3151851 T3 DK 3151851T3 DK 15728491 T DK15728491 T DK 15728491T DK 3151851 T3 DK3151851 T3 DK 3151851T3
Authority
DK
Denmark
Prior art keywords
complement
polymorphism
cat
patients
treatment
Prior art date
Application number
DK15728491.0T
Other languages
English (en)
Inventor
Wynne H Weston-Davies
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Application granted granted Critical
Publication of DK3151851T3 publication Critical patent/DK3151851T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK15728491.0T 2014-06-06 2015-06-08 Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme DK3151851T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Publications (1)

Publication Number Publication Date
DK3151851T3 true DK3151851T3 (da) 2022-02-28

Family

ID=51266841

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15728491.0T DK3151851T3 (da) 2014-06-06 2015-06-08 Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme
DK15807907.9T DK3302519T3 (da) 2014-06-06 2015-12-09 Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15807907.9T DK3302519T3 (da) 2014-06-06 2015-12-09 Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom

Country Status (16)

Country Link
US (3) US11052129B2 (da)
EP (1) EP3151851B1 (da)
JP (2) JP7045133B2 (da)
KR (1) KR102439717B1 (da)
CN (1) CN106659767B (da)
AU (1) AU2015270396B2 (da)
BR (1) BR112016028446A2 (da)
CA (1) CA2951175A1 (da)
DK (2) DK3151851T3 (da)
ES (2) ES2906630T3 (da)
GB (1) GB201410116D0 (da)
IL (1) IL249237B (da)
MX (1) MX2016016139A (da)
PL (2) PL3151851T3 (da)
RU (1) RU2700932C2 (da)
WO (1) WO2015185760A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3464351A1 (en) * 2016-06-07 2019-04-10 Novartis AG Anti-c5 antibody for treating patients with complement c5 polymorphism
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
WO2018193122A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
US20210113658A1 (en) * 2017-04-21 2021-04-22 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
WO2020053206A1 (en) * 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
MXPA05012880A (es) 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
JP2010502687A (ja) * 2006-09-08 2010-01-28 ヴァーレイ・リミテッド 呼吸器疾患の治療方法
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
JP5840623B2 (ja) * 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2018193122A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases

Also Published As

Publication number Publication date
CN106659767A (zh) 2017-05-10
IL249237B (en) 2020-09-30
US20170196936A1 (en) 2017-07-13
PL3151851T3 (pl) 2022-04-04
JP2017518316A (ja) 2017-07-06
NZ727053A (en) 2023-10-27
RU2016151179A (ru) 2018-07-16
RU2016151179A3 (da) 2019-01-22
CN106659767B (zh) 2022-08-30
CA2951175A1 (en) 2015-12-10
ES2906630T3 (es) 2022-04-19
RU2700932C2 (ru) 2019-09-24
KR20170016893A (ko) 2017-02-14
EP3151851B1 (en) 2021-12-01
US20180193417A1 (en) 2018-07-12
US11052129B2 (en) 2021-07-06
ES2906632T3 (es) 2022-04-19
JP7045133B2 (ja) 2022-03-31
DK3302519T3 (da) 2022-02-28
JP6767396B2 (ja) 2020-10-14
IL249237A0 (en) 2017-02-28
JP2018516944A (ja) 2018-06-28
EP3151851A1 (en) 2017-04-12
AU2015270396A1 (en) 2016-12-15
AU2015270396B2 (en) 2020-07-16
PL3302519T3 (pl) 2022-04-25
BR112016028446A2 (pt) 2017-10-24
KR102439717B1 (ko) 2022-09-02
MX2016016139A (es) 2017-07-28
US20210283221A1 (en) 2021-09-16
GB201410116D0 (en) 2014-07-23
WO2015185760A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3151851T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3590543T3 (da) Medicinsk forbinding
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK3474802T3 (da) Medicinsk forbinding
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3865484T3 (da) Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme
DK3119911T3 (da) Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3373874T3 (da) Medicinsk forbinding
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis